MC-Val-Cit-Doxorubicin CAS:159857-70-2 is a small molecule drug that is used in the treatment of certain types of cancer. It is composed of several functional groups, including a methoxypolyethylene glycol (MC) group, a valine-citrulline (Val-Cit) dipeptide linker, and a doxorubicin (Dox) group.
The MC group is a type of polyethylene glycol (PEG) spacer that is used to improve the solubility and stability of the drug in solution, allowing it to be more easily administered to patients. The Val-Cit dipeptide linker is used to connect the MC group to the Dox group, and it is designed to be selectively cleaved by enzymes that are present in certain types of cancer cells. This targeted delivery mechanism helps to minimize the toxicity of the drug to healthy cells, while maximizing its effectiveness against cancer cells.
The Dox group is a type of anthracycline antibiotic that is commonly used in the treatment of cancer. It works by inhibiting the synthesis of DNA and RNA in cancer cells, leading to cell death and tumor shrinkage. By combining the Dox group with the Val-Cit dipeptide linker and the MC spacer, MC-Val-Cit-Doxorubicin is able to selectively target cancer cells while minimizing toxicity to healthy cells.
MC-Val-Cit-Doxorubicin represents an important advance in the development of new drugs for the treatment of cancer. By combining multiple functional groups and using a targeted delivery mechanism, this drug has shown significant promise in improving outcomes for patients with certain types of cancer, and it holds great potential for future research and development in the field of cancer therapeutics.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
